The development of minimally invasive assays to detect gene mutations may provide a promising alternative to tumour biopsy, in the absence of available tissue samples, for identifying patients who would benefit from genotype-directed therapy such as EGFR-targeted agents. The gene discussed is EGFR; the disease is neoplasm.